After informed consent, patients were taken to the operating room for planned secondary cytoreduction. Random assignment occurred intraoperatively, after the surgeonconfirmed resectability to # 0.5 cm residual disease. Patients were stratified by platinum-free interval (6-12 months v . 12-30 months) and number of disease sites (single vmultiple). Patients with . 0.5 cm residual disease were not randomly assigned and replaced. Carboplatin was administered as HIPEC at 800 mg/m2 for 90 minutes at 41°C-43°C.